|
Aug 14
|
Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 12
|
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 12
|
Fate Therapeutics: Q2 Earnings Snapshot
|
|
Aug 12
|
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
|
|
Aug 11
|
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
|
|
Aug 7
|
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates
|
|
Aug 6
|
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 15
|
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
|
|
Jul 15
|
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
|
|
Jul 14
|
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
|
|
Jun 12
|
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
|
|
Feb 20
|
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 17
|
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
|
|
Feb 14
|
Fate Therapeutics to Present at Upcoming Investor Conferences
|
|
Sep 12
|
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
|
|
Jul 21
|
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
|
|
Jul 2
|
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 13
|
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
|
|
May 10
|
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
|